Stock Track | Monopar Therapeutics Plummets 7.48% Following Raymond James Downgrade

Stock Track

2025/11/14

Monopar Therapeutics (MNPR) saw its stock price plummet 7.48% in pre-market trading on Friday, following a downgrade from Raymond James. The investment firm lowered its rating on Monopar from Strong Buy to Outperform and cut its price target from $142 to $123.

The downgrade appears to have overshadowed positive sentiment from other analysts. Oppenheimer reiterated its Buy rating with a $115 price target, while BTIG maintained its Buy rating with a $104 target. Despite these bullish views, investors seem to be focusing on Raymond James' more cautious stance.

According to FactSet, Monopar Therapeutics still maintains an average rating of Buy among analysts, with a mean price target of $112. This suggests that while Raymond James has tempered its outlook, the overall sentiment remains positive. However, the market's sharp reaction indicates that investors are reassessing their expectations for the company in light of the downgrade.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1121303799"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1121303799\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1121303799?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 22:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121303799","market":"us","top_or_hot":-1,"title":"Stock Track | Monopar Therapeutics Plummets 7.48% Following Raymond James Downgrade","media":"Stock Track","content":"<p>Monopar Therapeutics (MNPR) saw its stock price plummet 7.48% in pre-market trading on Friday, following a downgrade from Raymond James. The investment firm lowered its rating on Monopar from Strong Buy to Outperform and cut its price target from $142 to $123.</p>\n\n<p>The downgrade appears to have overshadowed positive sentiment from other analysts. Oppenheimer reiterated its Buy rating with a $115 price target, while BTIG maintained its Buy rating with a $104 target. Despite these bullish views, investors seem to be focusing on Raymond James' more cautious stance.</p>\n\n<p>According to FactSet, Monopar Therapeutics still maintains an average rating of Buy among analysts, with a mean price target of $112. This suggests that while Raymond James has tempered its outlook, the overall sentiment remains positive. However, the market's sharp reaction indicates that investors are reassessing their expectations for the company in light of the downgrade.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Monopar Therapeutics Plummets 7.48% Following Raymond James Downgrade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Monopar Therapeutics Plummets 7.48% Following Raymond James Downgrade\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2025-11-14 22:33</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Monopar Therapeutics (MNPR) saw its stock price plummet 7.48% in pre-market trading on Friday, following a downgrade from Raymond James. The investment firm lowered its rating on Monopar from Strong Buy to Outperform and cut its price target from $142 to $123.</p>\n\n<p>The downgrade appears to have overshadowed positive sentiment from other analysts. Oppenheimer reiterated its Buy rating with a $115 price target, while BTIG maintained its Buy rating with a $104 target. Despite these bullish views, investors seem to be focusing on Raymond James' more cautious stance.</p>\n\n<p>According to FactSet, Monopar Therapeutics still maintains an average rating of Buy among analysts, with a mean price target of $112. This suggests that while Raymond James has tempered its outlook, the overall sentiment remains positive. However, the market's sharp reaction indicates that investors are reassessing their expectations for the company in light of the downgrade.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MNPR","symbol_name":"Monopar Therapeutics","start_time":0,"source_url":"","article_id":"1121303799","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121303799","pubTimestamp":1763130781,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Monopar Therapeutics (MNPR) saw its stock price plummet 7.48% in pre-market trading on Friday, following a downgrade from Raymond James. The investment firm lowered its rating on Monopar from Strong...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MNPR":"Monopar Therapeutics"},"translate_title":"个股追踪|Raymond James下调评级后Monopar Therapeutics暴跌7.48%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNPR":1},"content_text":"Monopar Therapeutics (MNPR) saw its stock price plummet 7.48% in pre-market trading on Friday, following a downgrade from Raymond James. The investment firm lowered its rating on Monopar from Strong Buy to Outperform and cut its price target from $142 to $123.\nThe downgrade appears to have overshadowed positive sentiment from other analysts. Oppenheimer reiterated its Buy rating with a $115 price target, while BTIG maintained its Buy rating with a $104 target. Despite these bullish views, investors seem to be focusing on Raymond James' more cautious stance.\nAccording to FactSet, Monopar Therapeutics still maintains an average rating of Buy among analysts, with a mean price target of $112. This suggests that while Raymond James has tempered its outlook, the overall sentiment remains positive. However, the market's sharp reaction indicates that investors are reassessing their expectations for the company in light of the downgrade.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}